Purpose Up to 20% of patients with biliary tract cancer (BTC) have alterations in DNA damage response (DDR) genes, including homologous recombination (HR) genes. Therefore, the DDR pathway could be a promising target for new drug development in BTC. We aim to investigate the anti-tumor effects using poly(ADP-ribose) polymerase (PARP) and WEE1 inhibitors in BTC.
Materials and Methods We used 10 BTC cell lines to evaluate an anti-tumor effect of olaparib (a PARP inhibitor) and AZD1775 (a WEE1 inhibitor) in in vitro. Additionally, we established SNU869 xenograft model for in vivo experiments.
Results In this study, we observed a modest anti-proliferative effect of olaparib. DNA double-strand break (DSB) and apoptosis were increased by olaparib in BTC cells. However, olaparib-induced DNA DSB was repaired through the HR pathway, and G2 arrest was induced to secure the time for repair. As AZD1775 typically regulates the G2/M checkpoint, we combined olaparib with AZD1775 to abrogate G2 arrest. We observed that AZD1775 downregulated p-CDK1, a G2/M cell cycle checkpoint protein, and induced early mitotic entry. AZD1775 also decreased CtIP and RAD51 expression and disrupted HR repair. In xenograft model, olaparib plus AZD1775 treatment reduced tumor growth more potently than did monotherapy with either drug.
Conclusion This is the first study to suggest that olaparib combined with AZD1775 can induce synergistic anti-tumor effects against BTC. Combination therapy that blocks dual PARP and WEE1 has the potential to be further clinically developed for BTC patients.
Citations
Citations to this article as recorded by
Current and Future Therapeutic Targets for Directed Molecular Therapies in Cholangiocarcinoma Philipp Heumann, Andreas Albert, Karsten Gülow, Denis Tümen, Martina Müller, Arne Kandulski Cancers.2024; 16(9): 1690. CrossRef
Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer Yijun Xie, Di Xiao, Duo Li, Mei Peng, Wei Peng, Huaxin Duan, Xiaoping Yang Frontiers in Oncology.2024;[Epub] CrossRef
Update on Combination Strategies of PARP Inhibitors Zhuoqun Lin, Lingfang Wang, Ziyu Xing, Fenfen Wang, Xiaodong Cheng Cancer Control.2024;[Epub] CrossRef
The mechanism and clinical application of DNA damage repair inhibitors combined with immune checkpoint inhibitors in the treatment of urologic cancer Deqian Xie, Bowen Jiang, Shijin Wang, Qifei Wang, Guangzhen Wu Frontiers in Cell and Developmental Biology.2023;[Epub] CrossRef
DNA Damage Response Inhibitors in Cholangiocarcinoma: Current Progress and Perspectives Öykü Gönül Geyik, Giulia Anichini, Engin Ulukaya, Fabio Marra, Chiara Raggi Cells.2022; 11(9): 1463. CrossRef
Targeted Therapy of HPV Positive and Negative Tonsillar Squamous Cell Carcinoma Cell Lines Reveals Synergy between CDK4/6, PI3K and Sometimes FGFR Inhibitors, but Rarely between PARP and WEE1 Inhibitors Ourania N. Kostopoulou, Mark Zupancic, Mariona Pont, Emma Papin, Monika Lukoseviciute, Borja Agirre Mikelarena, Stefan Holzhauser, Tina Dalianis Viruses.2022; 14(7): 1372. CrossRef
Targeted Therapy with PI3K, PARP, and WEE1 Inhibitors and Radiotherapy in HPV Positive and Negative Tonsillar Squamous Cell Carcinoma Cell Lines Reveals Synergy while Effects with APR-246 Are Limited Karin Byskata, Monika Lukoseviciute, Filippo Tuti, Mark Zupancic, Ourania N. Kostopoulou, Stefan Holzhauser, Tina Dalianis Cancers.2022; 15(1): 93. CrossRef
Purpose
Currently, the DNA damage response (DDR) pathway represents a key target for new cancer drug development. Advanced biliary tract cancer (BTC) has a poor prognosis because of the lack of efficacious treatment options. Although DNA repair pathway alterations have been reported in many patients with BTC, little is known regarding the effects of DDR-targeted agents against BTC.
Materials and Methods
In this study, nine BTC cell lines were exposed to the WEE1 inhibitor (AZD1775). In vitro, MTT assay, colony-forming assay, cell cycle analysis, phospho-histone H3 staining assay, Transwell migration assay, and western blot were performed. Then, to enhance the antitumor effect of AZD1775, the combination treatment of WEE1 inhibitor and ataxia telangiectasia mutated and Rad3 related (ATR) inhibitor (AZD6738) was conducted using MTT assay and comet assay. Finally, HuCCT-1 and SNU2670 xenograft models were established to confirm the anti-tumor effect of AZD1775 alone. Furthermore, the combination treatment was also evaluated in SNU2670 xenograft models.
Results
AZD1775 blocked the phosphorylation of CDC2 and CDC25C in all cell lines, but significantly increased apoptosis and S phase arrest in sensitive cells. However, increased p-ATR and phosphorylated ataxia telangiectasia mutated levels were observed in less sensitive cells. In addition, in vitro and in vivo data illustrated that AZD1775 combined with AZD6738 exerted more potent anti-tumor effects than either drug alone. Although WEE1 inhibition has promising anti-tumor effects in some BTC cells, the addition of ATR inhibitors could enhance its efficacy.
Conclusion
Taken together, this study supports further clinical development of DDR-targeted strategies as monotherapy or combination regimens for BTC.
Citations
Citations to this article as recorded by
Current and Future Therapeutic Targets for Directed Molecular Therapies in Cholangiocarcinoma Philipp Heumann, Andreas Albert, Karsten Gülow, Denis Tümen, Martina Müller, Arne Kandulski Cancers.2024; 16(9): 1690. CrossRef
Inhibition of the ATR-DNAPKcs-RB axis drives G1/S-phase transition and sensitizes triple-negative breast cancer (TNBC) to DNA holliday junctions Yue-miao Hu, Xue-cun Liu, Lei Hu, Zhi-wen Dong, Hong-ying Yao, Ying-jie Wang, Wen-jing Zhao, Yu-ke Xiang, Yi Liu, Hong-bo Wang, Qi-kun Yin Biochemical Pharmacology.2024; 225: 116310. CrossRef
Combination of S-1 and the oral ATR inhibitor ceralasertib is effective against pancreatic cancer cells Yoshihito Morimoto, Kimihiko Takada, Ami Nakano, Osamu Takeuchi, Kazuhiro Watanabe, Masayoshi Hirohara, Yutaka Masuda Cancer Chemotherapy and Pharmacology.2024; 94(6): 763. CrossRef
Immunomodulatory effects of trastuzumab deruxtecan through the cGAS-STING pathway in gastric cancer cells Kyoung-Seok Oh, Ah-Rong Nam, Ju-Hee Bang, Yoojin Jeong, Sea Young Choo, Hyo Jung Kim, Su In Lee, Jae-Min Kim, Jeesun Yoon, Tae-Yong Kim, Do-Youn Oh Cell Communication and Signaling.2024;[Epub] CrossRef
Targeting replication stress in cancer therapy Alexandre André B. A. da Costa, Dipanjan Chowdhury, Geoffrey I. Shapiro, Alan D. D’Andrea, Panagiotis A. Konstantinopoulos Nature Reviews Drug Discovery.2023; 22(1): 38. CrossRef
Combined Inhibition of Smoothened and the DNA Damage Checkpoint WEE1 Exerts Antitumor Activity in Cholangiocarcinoma Giulia Anichini, Chiara Raggi, Mirella Pastore, Laura Carrassa, Luisa Maresca, Enrica Crivaro, Tiziano Lottini, Lea Duwe, Jesper B. Andersen, Lorenzo Tofani, Luca Di Tommaso, Jesus M. Banales, Annarosa Arcangeli, Fabio Marra, Barbara Stecca Molecular Cancer Therapeutics.2023; 22(3): 343. CrossRef
Inhibiting WEE1 Augments the Antitumor Efficacy of Cisplatin in Urothelial Carcinoma by Enhancing the DNA Damage Process Yu-Li Su, Ling-Yi Xiao, Shih-Yu Huang, Chia-Che Wu, Li-Chung Chang, Yi-Hua Chen, Hao-Lun Luo, Chun-Chieh Huang, Ting-Ting Liu, Jei-Ming Peng Cells.2023; 12(11): 1471. CrossRef
The mechanism and clinical application of DNA damage repair inhibitors combined with immune checkpoint inhibitors in the treatment of urologic cancer Deqian Xie, Bowen Jiang, Shijin Wang, Qifei Wang, Guangzhen Wu Frontiers in Cell and Developmental Biology.2023;[Epub] CrossRef
Enrichment of Wee1/CDC2 and NF-κB Signaling Pathway Constituents Mutually Contributes to CDDP Resistance in Human Osteosarcoma Zhengbo Hu, Lugen Li, Wenxing Lan, Xiao Wei, Xiangyuan Wen, Penghuan Wu, Xianliao Zhang, Xinhua Xi, Yufa Li, Liqi Wu, Wenhu Li, Xiaohong Liao Cancer Research and Treatment.2022; 54(1): 277. CrossRef
ATR inhibitor AZD6738 increases the sensitivity of colorectal cancer cells to 5‑fluorouracil by inhibiting repair of DNA damage Takuya Suzuki, Takahisa Hirokawa, Anri Maeda, Shinnosuke Harata, Kaori Watanabe, Takeshi Yanagita, Hajime Ushigome, Nozomi Nakai, Yuzo Maeda, Kazuyoshi Shiga, Ryo Ogawa, Akira Mitsui, Masahiro Kimura, Yoichi Matsuo, Hiroki Takahashi, Shuji Takiguchi Oncology Reports.2022;[Epub] CrossRef
Inhibition of WEE1 Potentiates Sensitivity to PARP Inhibitor in Biliary Tract Cancer Hye-Rim Seo, Ah-Rong Nam, Ju-Hee Bang, Kyoung-Seok Oh, Jae-Min Kim, Jeesun Yoon, Tae-Yong Kim, Do-Youn Oh Cancer Research and Treatment.2022; 54(2): 541. CrossRef
DNA Damage Response Inhibitors in Cholangiocarcinoma: Current Progress and Perspectives Öykü Gönül Geyik, Giulia Anichini, Engin Ulukaya, Fabio Marra, Chiara Raggi Cells.2022; 11(9): 1463. CrossRef
Multiple-low-dose therapy: effective killing of high-grade serous ovarian cancer cells with ATR and CHK1 inhibitors Anya Golder, Louisa Nelson, Anthony Tighe, Bethany Barnes, Camilla Coulson-Gilmer, Robert D Morgan, Joanne C McGrail, Stephen S Taylor NAR Cancer.2022;[Epub] CrossRef
Differential Effects of Combined ATR/WEE1 Inhibition in Cancer Cells Gro Elise Rødland, Sissel Hauge, Grete Hasvold, Lilli T. E. Bay, Tine T. H. Raabe, Mrinal Joel, Randi G. Syljuåsen Cancers.2021; 13(15): 3790. CrossRef
Beyond the Double-Strand Breaks: The Role of DNA Repair Proteins in Cancer Stem-Cell Regulation Jacqueline Nathansen, Felix Meyer, Luise Müller, Marc Schmitz, Kerstin Borgmann, Anna Dubrovska Cancers.2021; 13(19): 4818. CrossRef
The Role of the Hedgehog Pathway in Cholangiocarcinoma Giulia Anichini, Laura Carrassa, Barbara Stecca, Fabio Marra, Chiara Raggi Cancers.2021; 13(19): 4774. CrossRef
Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract Cancers Chiao-En Wu, Yi-Ru Pan, Chun-Nan Yeh, John Lunec Biomolecules.2020; 10(11): 1474. CrossRef
Purpose
Pancreatic cancer (PC) is one of the most lethal cancers worldwide, but there are currently no effective treatments. The DNA damage response (DDR) is under investigation for the development of novel anti-cancer drugs. Since DNA repair pathway alterations have been found frequently in PC, the purpose of this study was to test the DDR-targeting strategy in PC using WEE1 and ATM inhibitors.
Materials and Methods
We performed in vitro experiments using a total of ten human PC cell lines to evaluate antitumor effect of AZD1775 (WEE1 inhibitor) alone or combination with AZD0156 (ATM inhibitor). We established Capan-1–mouse model for in vivo experiments to confirm our findings.
Results
In our research, we found that WEE1 inhibitor (AZD1775) as single agent showed anti-tumor effects in PC cells, however, targeting WEE1 upregulated p-ATM level. Here, we observed that co-targeting of WEE1 and ATM acted synergistically to reduce cell proliferation and migration, and to induce DNA damage in vitro. Notably, inhibition of WEE1 or WEE1/ATM downregulated programmed cell death ligand 1 expression by blocking glycogen synthase kinase-3β serine 9 phosphorylation and decrease of CMTM6 expression. In Capan-1 mouse xenograft model, AZD1775 plus AZD0156 (ATM inhibitor) treatment reduced tumor growth and downregulated tumor expression of programmed cell death ligand 1, CMTM6, CD163, and CXCR2, all of which contribute to tumor immune evasion.
Conclusion
Dual blockade of WEE1 and ATM might be a potential therapeutic strategy for PC. Taken toget
Citations
Citations to this article as recorded by
The Killer’s Web: Interconnection between Inflammation, Epigenetics and Nutrition in Cancer Marisabel Mecca, Simona Picerno, Salvatore Cortellino International Journal of Molecular Sciences.2024; 25(5): 2750. CrossRef
The molecular crosstalk between innate immunity and DNA damage repair/response: Interactions and effects in cancers Sahar Omidvar, Vahid Vahedian, Zahra Sourani, Davood Yari, Mehrdad Asadi, Negin Jafari, Lida Khodavirdilou, Molood Bagherieh, Moein Shirzad, Vahid Hosseini Pathology - Research and Practice.2024; 260: 155405. CrossRef
Progress of ATM inhibitors: opportunities and challenges Shan Du, Qi Liang, Jianyou Shi European Journal of Medicinal Chemistry.2024; : 116781. CrossRef
A prognostic risk model for ovarian cancer based on gene expression profiles from gene expression omnibus database Wei Fan, Xiaoyun Chen, Ruiping Li, Rongfang Zheng, Yunyun Wang, Yuzhen Guo Biochemical Genetics.2023; 61(1): 138. CrossRef
PGD2 displays distinct effects in diffuse large B-cell lymphoma depending on different concentrations Shunfeng Hu, Tiange Lu, Juanjuan Shang, Yiqing Cai, Mengfei Ding, Xiangxiang Zhou, Xin Wang Cell Death Discovery.2023;[Epub] CrossRef
The Landscape and Therapeutic Targeting of BRCA1, BRCA2 and Other DNA Damage Response Genes in Pancreatic Cancer Ioannis A. Voutsadakis, Antonia Digklia Current Issues in Molecular Biology.2023; 45(3): 2105. CrossRef
Bosutinib high density lipoprotein nanoformulation has potent tumour radiosensitisation effects Pouya Dehghankelishadi, Parisa Badiee, Michelle F. Maritz, Nicole Dmochowska, Benjamin Thierry Journal of Nanobiotechnology.2023;[Epub] CrossRef
Could Inhibiting the DNA Damage Repair Checkpoint Rescue Immune-Checkpoint-Inhibitor-Resistant Endometrial Cancer? Yinuo Li, Xiangyu Wang, Xin Hou, Xiangyi Ma Journal of Clinical Medicine.2023; 12(8): 3014. CrossRef
The mechanism and clinical application of DNA damage repair inhibitors combined with immune checkpoint inhibitors in the treatment of urologic cancer Deqian Xie, Bowen Jiang, Shijin Wang, Qifei Wang, Guangzhen Wu Frontiers in Cell and Developmental Biology.2023;[Epub] CrossRef
The DNA Damage Response and Inflammation in Cancer Vanessa Klapp, Beatriz Álvarez-Abril, Giuseppe Leuzzi, Guido Kroemer, Alberto Ciccia, Lorenzo Galluzzi Cancer Discovery.2023; 13(7): 1521. CrossRef
CMTM6, a potential immunotherapy target Jie Liang, Shaohua Li, Wei Li, Wei Rao, Shuo Xu, Haining Meng, Fengqi Zhu, Dongchang Zhai, Mengli Cui, Dan Xu, Jinzhen Cai, Bei Zhang Journal of Cancer Research and Clinical Oncology.2022; 148(1): 47. CrossRef
Loss of CMTM6 promotes DNA damage-induced cellular senescence and antitumor immunity Hanfeng Wang, Yang Fan, Weihao Chen, Zheng Lv, Shengpan Wu, Yundong Xuan, Chenfeng Wang, Yongliang Lu, Tao Guo, Donglai Shen, Fan Zhang, Qingbo Huang, Yu Gao, Hongzhao Li, Xin Ma, Baojun Wang, Yan Huang, Xu Zhang OncoImmunology.2022;[Epub] CrossRef
Cell cycle checkpoints and beyond: Exploiting the ATR/CHK1/WEE1 pathway for the treatment of PARP inhibitor–resistant cancer Nitasha Gupta, Tzu-Ting Huang, Sachi Horibata, Jung-Min Lee Pharmacological Research.2022; 178: 106162. CrossRef
DNA damage response inhibition‐based combination therapies in cancer treatment: Recent advances and future directions Tianen Chen, Suparat Tongpeng, Ziyi Lu, Win Topatana, Sarun Juengpanich, Shijie Li, Jiahao Hu, Jiasheng Cao, Cheeshin Lee, Yitong Tian, Mingyu Chen, Xiujun Cai Aging and Cancer.2022; 3(1): 44. CrossRef
The clinical and prognostic significance of CMTM6/PD-L1 in oncology Mahmoud Mohammad Yaseen, Nizar Mohammad Abuharfeil, Homa Darmani Clinical and Translational Oncology.2022; 24(8): 1478. CrossRef
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment Giulia Petroni, Aitziber Buqué, Lisa M. Coussens, Lorenzo Galluzzi Nature Reviews Drug Discovery.2022; 21(6): 440. CrossRef
CMTM6 as a master regulator of PD-L1 Mahmoud Mohammad Yaseen, Nizar Mohammad Abuharfeil, Homa Darmani Cancer Immunology, Immunotherapy.2022; 71(10): 2325. CrossRef
Targeting protein kinases benefits cancer immunotherapy Zhengkun Zhang, Lang Bu, Junhang Luo, Jianping Guo Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2022; 1877(4): 188738. CrossRef
CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment Tong Zhang, Haixiang Yu, Xiangpeng Dai, Xiaoling Zhang Frontiers in Immunology.2022;[Epub] CrossRef
The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy Congqi Shi, Kaiyu Qin, Anqi Lin, Aimin Jiang, Quan Cheng, Zaoqu Liu, Jian Zhang, Peng Luo Journal of Experimental & Clinical Cancer Research.2022;[Epub] CrossRef
CMTM6 as a candidate risk gene for cervical cancer: Comprehensive bioinformatics study Xiaoting Huang, Wei Liu, Chunshan Liu, Jijie Hu, Baiyao Wang, Anbang Ren, Xiaona Huang, Yawei Yuan, Jinquan Liu, Mingyi Li Frontiers in Molecular Biosciences.2022;[Epub] CrossRef
DNA damaging agents and DNA repair: From carcinogenesis to cancer therapy Larissa Costa de Almeida, Felipe Antunes Calil, João Agostinho Machado-Neto, Leticia Veras Costa-Lotufo Cancer Genetics.2021; 252-253: 6. CrossRef
Immunomodulation by targeted anticancer agents Giulia Petroni, Aitziber Buqué, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi Cancer Cell.2021; 39(3): 310. CrossRef
Targeting WEE1 by adavosertib inhibits the malignant phenotypes of hepatocellular carcinoma Jian Chen, Xing Jia, Zequn Li, Wenfeng Song, Cheng Jin, Mengqiao Zhou, Haiyang Xie, Shusen Zheng, Penghong Song Biochemical Pharmacology.2021; 188: 114494. CrossRef
WEE1 inhibition reverses trastuzumab resistance in HER2-positive cancers Mei-Hua Jin, Ah-Rong Nam, Ju-Hee Bang, Kyoung-Seok Oh, Hye-Rim Seo, Jae-Min Kim, Jeesun Yoon, Tae-Yong Kim, Do-Youn Oh Gastric Cancer.2021; 24(5): 1003. CrossRef
ATR inhibition amplifies antitumor effects of olaparib in biliary tract cancer Ah-Rong Nam, Jeesun Yoon, Mei-Hua Jin, Ju-Hee Bang, Kyoung-Seok Oh, Hye-Rim Seo, Jae-Min Kim, Tae-Yong Kim, Do-Youn Oh Cancer Letters.2021; 516: 38. CrossRef
Development of Immunotherapy Combination Strategies in Cancer Timothy A. Yap, Eileen E. Parkes, Weiyi Peng, Justin T. Moyers, Michael A. Curran, Hussein A. Tawbi Cancer Discovery.2021; 11(6): 1368. CrossRef
Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities Aditi Jain, Vikas Bhardwaj World Journal of Gastroenterology.2021; 27(39): 6527. CrossRef
A steroidal saponin isolated from Allium chinense simultaneously induces apoptosis and autophagy by modulating the PI3K/Akt/mTOR signaling pathway in human gastric adenocarcinoma Jingwen Xu, Mingmei Zhang, Xiaoying Lin, Yihai Wang, Xiangjiu He Steroids.2020; : 108672. CrossRef
Purpose
The DNA damage response (DDR) is a multi-complex network of signaling pathways involved in DNA damage repair, cell cycle checkpoints, and apoptosis. In the case of biliary tract cancer (BTC), the strategy of DDR targeting has not been evaluated, even though many patients have DNA repair pathway alterations. The purpose of this study was to test the DDR-targeting strategy in BTC using an ataxia-telangiectasia and Rad3-related (ATR) inhibitor.
Materials and Methods
A total of nine human BTC cell lines were used for evaluating anti-tumor effect of AZD6738 (ATR inhibitor) alone or combination with cytotoxic chemotherapeutic agents through MTT assay, colony-forming assays, cell cycle analyses, and comet assays. We established SNU478-mouse model for in vivo experiments to confirm our findings.
Results
Among nine human BTC cell lines, SNU478 and SNU869 were the most sensitive to AZD6738, and showed low expression of both ataxia-telangiectasia mutated (ATM) and p53. AZD6738 blocked p-Chk1 and p-glycoprotein and increased γH2AX, a marker of DNA damage, in sensitive cells. AZD6738 significantly increased apoptosis, G2/M arrest and p21, and decreased CDC2. Combinations of AZD6738 and cytotoxic chemotherapeutic agents exerted synergistic effects in colony-forming assays, cell cycle analyses, and comet assays. In our mouse models, AZD6738 monotherapy decreased tumor growth and the combination with cisplatin showed more potent effects on growth inhibition, decreased Ki-67, and increased terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling than monotherapy with each drug.
Conclusion
In BTC, DDR targeting strategy using ATR inhibitor demonstrated promising antitumor activity alone or in combination with cytotoxic chemotherapeutic agents. This supports further clinical development of DDR targeting strategy in BTC.
Citations
Citations to this article as recorded by
“Convex Lens” of DNA damage: A nanomedicine enhances anti-PD-1 immunotherapy as immunogenic cell death inducer for “cold” melanoma Wenjun Wang, Yu Liu, Dong Chen, Jiajia Pang, Chunyu Lai, Mingbao Gu, Meilun Zhai, Qian Yu, Yang Wang, Xuanwen Bao, Yangyang Li, Xiaomeng Dai, Dong Chen, Peng Zhao, Jinghong Xu, Rui Lei Nano Today.2025; 61: 102598. CrossRef
DNA damage response mutations enhance the antitumor efficacy of ATR and PARP inhibitors in cholangiocarcinoma cell lines Tassanee Lerksuthirat, Sunisa Prasopporn, Rakkreat Wikiniyadhanee, Sermsiri Chitphuk, Wasana Stitchantrakul, Paravee Owneium, Siwanon Jirawatnotai, Donniphat Dejsuphong Oncology Letters.2025;[Epub] CrossRef
Ataxia telangiectasia and Rad3-related (ATR) inhibition by VE-822 potently reversed 5-flourouracil resistance in colorectal cancer cells through targeting DNA damage response Ainaz Mihanfar, Faezeh Asghari, Maryam Majidinia Molecular Biology Reports.2024;[Epub] CrossRef
Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer Yijun Xie, Di Xiao, Duo Li, Mei Peng, Wei Peng, Huaxin Duan, Xiaoping Yang Frontiers in Oncology.2024;[Epub] CrossRef
Therapeutic Targeting of DNA Replication Stress in Cancer Long Gu, Robert J. Hickey, Linda H. Malkas Genes.2023; 14(7): 1346. CrossRef
CRISPR screens guide the way for PARP and ATR inhibitor biomarker discovery Emily M. Schleicher, George‐Lucian Moldovan The FEBS Journal.2022; 289(24): 7854. CrossRef
Inhibition of WEE1 Potentiates Sensitivity to PARP Inhibitor in Biliary Tract Cancer Hye-Rim Seo, Ah-Rong Nam, Ju-Hee Bang, Kyoung-Seok Oh, Jae-Min Kim, Jeesun Yoon, Tae-Yong Kim, Do-Youn Oh Cancer Research and Treatment.2022; 54(2): 541. CrossRef
DNA Damage Response Inhibitors in Cholangiocarcinoma: Current Progress and Perspectives Öykü Gönül Geyik, Giulia Anichini, Engin Ulukaya, Fabio Marra, Chiara Raggi Cells.2022; 11(9): 1463. CrossRef
Aging and biliary tract cancers: Epidemiology, molecular biology, and clinical practice Xiaoling Weng, Xiaoling Song, Rong Shao, Fatao Liu, Yingbin Liu Aging and Cancer.2022; 3(2): 95. CrossRef
AZD6738 Inhibits fibrotic response of conjunctival fibroblasts by regulating checkpoint kinase 1/P53 and PI3K/AKT pathways Longxiang Huang, Qin Ye, Chunlin Lan, Xiaohui Wang, Yihua Zhu Frontiers in Pharmacology.2022;[Epub] CrossRef
AZD6738 decreases intraocular pressure and inhibits fibrotic response in trabecular meshwork through CHK1/P53 pathway Longxiang Huang, Zhenni Wei, Xiaohui Wang, Chunlin Lan, Yihua Zhu, Qin Ye Biochemical Pharmacology.2022; 206: 115340. CrossRef
Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer Jin Hur, Mithun Ghosh, Tae Heon Kim, Nahee Park, Kamal Pandey, Young Bin Cho, Sa Deok Hong, Nar Bahadur Katuwal, Minsil Kang, Hee Jung An, Yong Wha Moon International Journal of Molecular Sciences.2021; 22(3): 1223. CrossRef
ATR inhibition amplifies antitumor effects of olaparib in biliary tract cancer Ah-Rong Nam, Jeesun Yoon, Mei-Hua Jin, Ju-Hee Bang, Kyoung-Seok Oh, Hye-Rim Seo, Jae-Min Kim, Tae-Yong Kim, Do-Youn Oh Cancer Letters.2021; 516: 38. CrossRef
Targeting Cellular DNA Damage Responses in Cancer: An In Vitro-Calibrated Agent-Based Model Simulating Monolayer and Spheroid Treatment Responses to ATR-Inhibiting Drugs Sara Hamis, James Yates, Mark A. J. Chaplain, Gibin G. Powathil Bulletin of Mathematical Biology.2021;[Epub] CrossRef
The Role of the Hedgehog Pathway in Cholangiocarcinoma Giulia Anichini, Laura Carrassa, Barbara Stecca, Fabio Marra, Chiara Raggi Cancers.2021; 13(19): 4774. CrossRef
Targeting the DNA damage response: PARP inhibitors and new perspectives in the landscape of cancer treatment Sofia Genta, Federica Martorana, Anastasios Stathis, Ilaria Colombo Critical Reviews in Oncology/Hematology.2021; 168: 103539. CrossRef
Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer Ah-Rong Nam, Mei-Hua Jin, Ju-Hee Bang, Kyoung-Seok Oh, Hye-Rim Seo, Do-Youn Oh, Yung-Jue Bang Cancer Research and Treatment.2020; 52(3): 945. CrossRef
Drug resistance in cancer: mechanisms and tackling strategies Tanweer Haider, Vikas Pandey, Nagma Banjare, Prem N. Gupta, Vandana Soni Pharmacological Reports.2020; 72(5): 1125. CrossRef
Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract Cancers Chiao-En Wu, Yi-Ru Pan, Chun-Nan Yeh, John Lunec Biomolecules.2020; 10(11): 1474. CrossRef
The Cancer Stem Cell Inhibitor Napabucasin (BBI608) Shows General Cytotoxicity in Biliary Tract Cancer Cells and Reduces Cancer Stem Cell Characteristics Marlena Beyreis, Martin Gaisberger, Martin Jakab, Daniel Neureiter, Katharina Helm, Markus Ritter, Tobias Kiesslich, Christian Mayr Cancers.2019; 11(3): 276. CrossRef
Inhibition of Wee1 sensitizes AML cells to ATR inhibitor VE-822-induced DNA damage and apoptosis Wenxiu Qi, Xiaohao Xu, Manying Wang, Xiangyan Li, Chaonan Wang, Liping Sun, Daqing Zhao, Liwei Sun Biochemical Pharmacology.2019; 164: 273. CrossRef
Purpose
Heterochromatin protein 1γ (HP1γ) interacts with chromosomes by binding to lysine 9-methylated histone H3 or DNA/RNA. HP1γ is involved in various biological processes. The purpose of this study is to gain an understanding of how HP1γ functions in these processes by identifying HP1γ-binding proteins using mass spectrometry.
Materials and Methods
We performed affinity purification of HP1γ-binding proteins using G1/S phase or prometaphase HEK293T cell lysates that transiently express mock or FLAG-HP1γ. Coomassie staining was performed for HP1γ-binding complexes, using cell lysates prepared by affinity chromatography FLAG-agarose beads, and the bands were digested and then analyzed using a mass spectrometry.
Results
We identified 99 HP1γ-binding proteins with diverse cellular functions, including spliceosome, regulation of the actin cytoskeleton, tight junction, pathogenic Escherichia coli infection, mammalian target of rapamycin signaling pathway, nucleotide excision repair, DNA replication, homologous recombination, and mismatch repair.
Conclusion
Our results suggested that HP1γ is functionally active in DNA damage response via proteinprotein interaction.
Citations
Citations to this article as recorded by
Inhibition of annexin A7 suppresses senescence‐associated heterochromatin foci formation and senescence through the AMPK/mTOR pathway in human dermal fibroblasts Nan Li, Xiaomeng Yan, Xiaoling Cui, Congyao Zhao, Zhaomin Lin, Junying Miao Journal of Cellular Biochemistry.2023; 124(10): 1603. CrossRef
Clinicopathological significance of CBX3 in colorectal cancer: An intensive expression study based on formalin‐fixed and paraffin‐embedded tissues Hai Wang, Wenyue Zhao, Jiandong Wang, Zhiyuan Zhang Pathology International.2022; 72(2): 107. CrossRef
Discovery, expression, cellular localization, and molecular properties of a novel, alternative spliced HP1γ isoform, lacking the chromoshadow domain Angela Mathison, Thiago Milech De Assuncao, Nikita R. Dsouza, Monique Williams, Michael T. Zimmermann, Raul Urrutia, Gwen Lomberk, Albert Jeltsch PLOS ONE.2020; 15(2): e0217452. CrossRef
CBX3 Promotes Gastric Cancer Progression and Affects Factors Related to Immunotherapeutic Responses
Hexin Lin, Jiabian Lian, Lu Xia, Guoxian Guan, Jun You Cancer Management and Research.2020; Volume 12: 10113. CrossRef
Cbx3 inhibits vascular smooth muscle cell proliferation, migration, and neointima formation Cheng Zhang, Dan Chen, Eithne Margaret Maguire, Shiping He, Jiangyong Chen, Weiwei An, Mei Yang, Tayyab Adeel Afzal, Le Anh Luong, Li Zhang, Han Lei, Qingchen Wu, Qingzhong Xiao Cardiovascular Research.2018; 114(3): 443. CrossRef